Выходит 6 номеров в год
ISSN Печать: 0743-4863
ISSN Онлайн: 2162-660X
Indexed in
Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis
Краткое описание
Rheumatoid arthritis (RA) is a very painful severe autoimmune disease with complex pathology characterized by progressive chronic inflammation, and devastation of the synovium, cartilage, and other joint-associated structures. Significant advances in research in the area of pathophysiology, diagnosis, drug development, and targeted delivery have led to improved RA therapy and better patient compliance. Targeted drug delivery using liposomal nanomedicines significantly alleviate the challenges with conventional anti-RA medications such as off-target effects, short biological half-life, poor bioavailability, high dose-related toxicity, etc. Liposomal nanomedicines in RA drug targeting offer the opportunity for passive targeting [based on size and polyethylene glycol (PEG)-ylation-mediated enhanced permeability and retention] and active targeting (ligation with antibody or peptides, etc.) and encapsulation of lipophilic, hydrophilic drugs, and/or combinational drugs. However, it has been found recently that such injectable nanomedicines raise the concern of an adverse immune phenomenon called complement activationrelated pseudo allergy (CARPA) and failure of therapy on multiple doses due to accelerated body clearance caused many by anti-PEG immunoglobulin M. To ensure safety and efficacy of RA therapy, these need to be considered along with the common formulation quality parameters. Here, we discuss nanotherapeutic targeting in RA therapy using liposomes. Liposomal nanoparticles are investigated for individual anti-RA drug categories. CARPA issues and pathophysiology with such nanomedicines are also discussed in detail.
-
Knauer Nadezhda, Pashkina Ekaterina, Apartsin Evgeny, Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins, Pharmaceutics, 11, 2, 2019. Crossref
-
Chavan Tejashri, Muttil Pavan, Kunda Nitesh K., Introduction to Nanomedicine in Drug Delivery, in Mucosal Delivery of Drugs and Biologics in Nanoparticles, 41, 2020. Crossref
-
Sehnert Bettina, Burkhardt Harald, Dübel Stefan, Voll Reinhard E., Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases, Cells, 9, 7, 2020. Crossref
-
Song Yanqin, Ismail Muhammad, Shan Qi, Zhao Jianing, Zhu Yanping, Zhang Leiming, Du Yuan, Ling Longbing, ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways, Nanoscale, 13, 47, 2021. Crossref
-
Tu Allen B., Lewis Jamal S., Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis, Drug Delivery and Translational Research, 11, 6, 2021. Crossref
-
Abdellatif Ahmed A. H., Mohammed Hamdoon A., Khan Riaz A., Singh Varsha, Bouazzaoui Abdellatif, Yusuf Mohammad, Akhtar Naseem, Khan Maria, Al-Subaiyel Amal, Mohammed Salman A. A., Al-Omar Mohsen S., Nano-scale delivery: A comprehensive review of nano-structured devices, preparative techniques, site-specificity designs, biomedical applications, commercial products, and references to safety, cellular uptake, and organ toxicity, Nanotechnology Reviews, 10, 1, 2021. Crossref
-
Guo Rui-bo, Zhang Xin-yue, Yan De-kang, Yu Ying-jie, Wang Yu-jia, Geng Hong-xia, Wu Ya-nan, Liu Yang, Kong Liang, Li Xue-tao, Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy, Biomaterials Science, 10, 2, 2022. Crossref
-
Ramalingam Prakash, Prabakaran D. S., Sivalingam Kalaiselvi, Nallal V. Uma Maheshwari, Razia M., Patel Mayurkumar, Kanekar Tanvi, Krishnamoorthy Dineshkumar, Recent Advances in Nanomaterials-Based Drug Delivery System for Cancer Treatment, in Emerging Nanomaterials for Advanced Technologies, 2022. Crossref
-
Ma Luoyang, Zheng Xiaoyan, Lin Rui, Sun Antonia RuJia, Song Jintong, Ye Zhiqiang, Liang Dahong, Zhang Min, Tian Jia, Zhou Xin, Cui Liao, Liu Yuyu, Liu Yanzhi, Knee Osteoarthritis Therapy: Recent Advances in Intra-Articular Drug Delivery Systems, Drug Design, Development and Therapy, Volume 16, 2022. Crossref